Dhofar Pharmaceutical Industries in Oman launches first locally made IV solutions

OMAN—Dhofar Pharmaceutical Industries has introduced its first range of intravenous (IV) and kidney dialysis solutions to the Omani market, marking a significant breakthrough for the country’s healthcare sector.

The Ministry of Health approved the release after the company successfully met all technical requirements and passed comprehensive safety testing protocols.

This development represents a crucial step toward reducing Oman’s dependence on imported medical supplies while strengthening the nation’s drug security framework.

Local production of these essential medical fluids addresses a longstanding vulnerability in the healthcare supply chain, particularly critical given recent global disruptions to international trade networks.

A decade in the making

Sheikh Salem bin Ali Amer Jaid al Mahri, a prominent businessman from Dhofar Governorate, initiated this project over ten years ago after observing the country’s heavy reliance on foreign medical products.

He recognized the strategic importance of establishing domestic manufacturing capabilities for critical clinical supplies that hospitals and healthcare facilities require daily.

The journey from concept to completion presented numerous challenges.

High operational costs, complex logistical demands, and the unprecedented disruptions caused by the COVID-19 pandemic tested the company’s resolve.

Nevertheless, Sheikh al Mahri and his team persevered, maintaining their focus on building a sustainable domestic supply chain to reliably serve Oman’s healthcare needs.

State-of-the-art manufacturing

The company operates from an advanced facility located in Raysut Industrial City, where it employs cutting-edge technologies to manufacture medical solutions that meet international quality standards.

This modern infrastructure enables the production of IV fluids and dialysis solutions that match the specifications and safety profiles of imported alternatives.

The facility’s capabilities extend beyond basic production, incorporating quality control measures and testing procedures that align with global pharmaceutical manufacturing standards.

This ensures that healthcare providers can trust locally produced solutions to deliver therapeutic outcomes equivalent to those of their imported counterparts.

Aligning with National Vision

This initiative directly supports Oman Vision 2040, the national strategic framework that prioritizes industrial diversification and self-sufficiency in essential sectors.

By manufacturing critical medical supplies domestically, the country reduces its exposure to international market volatility, currency fluctuations, and supply chain disruptions that can threaten healthcare delivery.

The project also contributes to economic diversification efforts by creating local employment opportunities and fostering technical expertise within Oman’s industrial sector.

As the company expands its production capabilities, it positions the Sultanate as a potential regional hub for pharmaceutical manufacturing, opening possibilities for future export markets beyond domestic consumption.

Dhofar Pharmaceutical Industries’ achievement demonstrates how strategic investment in local manufacturing can enhance national resilience while supporting broader economic development goals in the healthcare sector.